Continuous rhPTH (1-34) treatment in chronic hypoparathyroidism

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pharmacology

Background:

• Standard hypoparathyroidism treatment with calcium and vitamin D analogues often fails to restore calcium homeostasis.
• Some patients develop treatment-refractory hypoparathyroidism with persistent hypocalcemia and complications.
• Subcutaneous recombinant human parathyroid hormone (rhPTH) administered intermittently shows only temporary efficacy.

Purpose of the Study:

• To evaluate the efficacy of continuous subcutaneous infusion of rhPTH (1-34) via insulin pump in patients with severe, treatment-refractory hypoparathyroidism.
• To assess the long-term stabilization of calcium and phosphate levels with this novel delivery method.
• To determine if continuous rhPTH infusion can reduce or eliminate the need for conventional treatments and intravenous calcium supplementation.

Main Methods:

• Three patients with severe postsurgical hypoparathyroidism refractory to standard and intermittent subcutaneous rhPTH treatment were included.
• Treatment involved continuous subcutaneous infusion of rhPTH (1-34) using an insulin pump at daily doses ranging from 15 µg to 29.4 µg.
• Serum calcium and phosphate levels were monitored, and conventional treatments (oral calcium, vitamin D, intravenous calcium) were adjusted accordingly.

Main Results:

• Continuous subcutaneous rhPTH (1-34) infusion normalized serum calcium and phosphate levels within one week in all three patients.
• Oral vitamin D and calcium supplementation could be reduced or discontinued.
• Intravenous calcium administration became unnecessary, and treatment efficacy was sustained for up to 7 years.

Conclusions:

• Continuous subcutaneous administration of rhPTH (1-34) via insulin pump is a successful alternative treatment for hypoparathyroidism refractory to conventional therapies and intermittent subcutaneous rhPTH.
• This delivery method offers long-term stabilization of calcium and phosphate homeostasis.
• It significantly improves patient management by reducing reliance on frequent intravenous calcium infusions and oral supplements.